4 nominees · 7 ballot items.
Election of four Class I directors; ratification of Ernst & Young LLP as independent auditor and authorization to set its remuneration; advisory approval of named executive officer compensation and advisory vote on the frequency of such votes; authorization to make market purchases of ordinary shares; authorization to set the price range for re-allotment of treasury shares; and approval of a capital reduction to create distributable reserves.
Elect, by separate resolutions, four Class I director nominees (Racquel Harris Mason, Todd Lachman, Charlotte Simonelli, Gabriela Weiss) to serve three-year terms until the 2029 annual general meeting.
Ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company’s independent auditor for fiscal year ending December 31, 2026 and authorize the audit committee to set the auditor’s remuneration (binding).
Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the Compensation Discussion and Analysis and related disclosures for fiscal 2025.
This is a non-binding advisory “say-on-pay” vote asking shareholders to approve the Company’s fiscal 2025 named executive officer (NEO) compensation as disclosed in the proxy (CD&A, compensation tables and narrative). Management seeks this advisory approval to confirm shareholder support for its pay philosophy, which emphasizes market-competitive pay, pay-for-performance through an Annual Incentive Plan (AIP) and long-term equity awards, and governance features such as stock ownership guidelines, clawback policy and prohibited hedging. The CD&A describes how AIP metrics (Adjusted EBITDA, Revenue, Free Cash Flow) and multi-year restricted share units and phantom units link pay to short- and long-term performance; the compensation committee engaged an independent consultant (Meridian) and uses a peer group for benchmarking. Although the vote is non-binding, the board and compensation committee state they will consider the outcome when setting future compensation arrangements, making this an important governance signal. Key trade-offs include reliance on internal AIP metrics (with adjustments), significant equity-based compensation that is sensitive to share price performance, and retention-focused features such as multi-year vesting and post-IPO treatment of pre-IPO awards. The proposal’s approval supports continuity in current pay design; a negative result would likely prompt management and the compensation committee to reassess plan design and investor engagement. Given the Company’s recent IPO, equity conversion/treatment of pre-IPO awards and recoupment (clawback) rules are germane context for evaluating whether pay aligns with realized shareholder outcomes. In sum, shareholders are asked to endorse the overall executive pay approach rather than any single element of compensation, with the board committing to consider the advisory result in future decisions.
Non-binding advisory vote to select whether future advisory votes on named executive officer compensation should occur once every one, two, or three years; board recommends a one-year frequency.
This advisory proposal asks shareholders to choose the frequency (one, two, or three years) for future non-binding say-on-pay votes; management recommends an annual vote. Management argues annual votes maintain ongoing shareholder engagement and timely feedback on compensation decisions, particularly given the Company’s recent IPO and evolving compensation arrangements. An annual cadence enables shareholders to react to year-to-year performance and compensation outcomes (e.g., AIP results, equity vesting and share price movement), while less frequent votes reduce administrative burden but limit responsiveness. Because the vote is advisory, the board is not legally bound by the outcome but has stated it will consider the shareholders’ preference. A plurality rule applies, meaning the option with the most votes wins; investors should consider the trade-offs between governance responsiveness and potential vote fatigue. In the context of NIQ’s governance, frequent (annual) votes may be preferable to monitor alignment of pay with rapidly changing post-IPO metrics and to ensure the compensation committee’s approach remains acceptable to public-market investors. Management’s recommendation for one year signals a desire for continuous shareholder feedback and provides a mechanism for investors to register approval or concerns about short-term and long-term pay practices.
Authorize the Company and any subsidiary to make market purchases and overseas market purchases of ordinary shares (up to 29,511,527 shares, ~10% of issued shares), with a maximum price of 110% of the NYSE closing price and a minimum of par value, effective for 18 months.
This management proposal requests shareholder approval to authorize on-market and overseas market purchases of up to roughly 10% of the company’s issued ordinary shares over an 18-month period, with a price cap of 110% of the NYSE closing price and a floor at nominal value. Under Irish law, such market purchase authority for the Company and its subsidiaries requires shareholder approval; management is seeking flexibility to execute repurchases, redemptions, or overseas market purchases (on recognized exchanges such as the NYSE) when price and capital conditions make repurchases attractive. The repurchase authority can be used for capital allocation (returning capital to shareholders), balance sheet management, or to provide treasury shares for compensation programs, but it carries governance considerations including potential impacts on free float, EPS, and minority shareholder liquidity. The 110% cap limits extreme premium purchases and the 18-month expiration ensures periodic shareholder reauthorization and oversight. The resolution contemplates board discretion as to timing and manner of repurchases and allows completion of contracts entered into before expiry, a common practical provision. For investors, the proposal’s approval signals management’s intention to actively manage capital structure post-IPO and gives the board tools to respond to market conditions; downside risks include potential perception of opportunistic buybacks or depletion of capital that could otherwise fund growth. Overall, the proposal is a standard corporate finance authorization to enable buybacks, subject to prudent board exercise of discretion and compliance with Irish statutory requirements.
Authorize the Company to re-allot treasury shares at prices between 95% and 120% of the 30-day average NYSE closing price (minimum nominal value for employee share plans), effective for 18 months, to facilitate re-allotment of treasury shares including for employee compensation plans.
This special resolution seeks shareholder approval to set the permissible price range for re-allotting treasury shares—maximum 120% and minimum 95% of the 30-day NYSE average—or par value where shares satisfy employee plan obligations—valid for 18 months. Under Irish law, shareholders must authorize the price bands for re-allotment of treasury shares; this resolution provides the board with the flexibility to reissue treasury shares (including for equity compensation plans) at market-referenced prices while protecting against re-issues at extreme discounts or premiums. The 95%-120% band is consistent with common practice allowing modest discounting for market mechanics but preventing dilution at materially discounted levels; par value floor for employee plans preserves ability to satisfy contractual employee awards. The authority’s limited duration ensures regular shareholder review while enabling practical administration of compensation programs and capital management. From a governance perspective, approval facilitates the company’s ability to use treasury shares efficiently for retention and reward programs without requiring separate shareholder approvals for each allotment, but shareholders should weigh potential dilution and timing/price risks. Management frames the proposal as routine and necessary for effective equity compensation and treasury management post-IPO.
Approve cancellation of the Company’s entire share premium account (approximately $2.941 billion) and creation of an equal distributable reserve subject to confirmation by the Irish High Court, enabling the Company to make distributions, repurchases or dividends from those reserves.
This special resolution requests shareholders to authorize a capital reduction to cancel up to $2.941 billion of the Company’s share premium account and reclassify that amount as distributable reserves, subject to confirmation by the Irish High Court. The primary rationale is legal: under Irish law distributable reserves (profits available for distribution) are required to fund dividends, share repurchases and other distributions, whereas share premium is not distributable; converting share premium into distributable reserves therefore materially increases the Company’s flexibility for capital returns and treasury actions. The proposal requires both shareholder approval (75% special resolution threshold) and court confirmation under Sections 84–85 of the Companies Act 2014; while management expects confirmation, court approval is discretionary and not guaranteed. For investors, this change would enable future dividends or buybacks without the additional step of creating distributable reserves each time, accelerating capital-return options post-IPO, but it is not itself a decision to pay dividends or buy back shares. The board’s proposal notes the Reorganization and IPO created significant share premium, motivating the request; the proposed authorization also delegates operational execution to the board and officers to seek court confirmation and implement the reduction. Key considerations for shareholders include potential future use of the distributable reserves, timing and governance of any distributions, and the legal process and protections surrounding the capital reduction.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ADVENT INTERNATIONAL, L.P. | 50.61% | 149,380,246 | $1.7B |
| 2 | Kohlberg Kravis Roberts Co. L.P. | 10.17% | 30,022,789 | $341M |
| 3 | SurgoCap Partners LP | 1.98% | 5,858,000 | $67M |
| 4 | Alamut Investment Management LLP | 1.26% | 3,731,115 | $42M |
| 5 | JNE Partners LLP | 1.26% | 3,729,938 | $42M |
| 6 | DnB Asset Management AS | 1.24% | 3,661,841 | $42M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1.19% | 3,516,617 | $40M |
| 8 | Alyeska Investment Group, L.P. | 1.19% | 3,512,388 | $40M |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.11% | 3,289,854 | $37M |
| 10 | UBS Group AG | 1.05% | 3,092,991 | $35M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.